Symbols / XRTX $2.28 -1.51% XORTX Therapeutics Inc.
XRTX Chart
About
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 19.37M |
| Enterprise Value | 2.16M | Income | -2.66M | Sales | — |
| Book/sh | 0.30 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 2.85 | PEG | — |
| P/S | — | P/B | 7.64 | P/C | — |
| EV/EBITDA | -0.86 | EV/Sales | — | Quick Ratio | 1.58 |
| Current Ratio | 2.10 | Debt/Eq | 1.79 | LT Debt/Eq | — |
| EPS (ttm) | -2.80 | EPS next Y | 0.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -46.84% |
| ROE | -98.00% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.39M |
| Shs Float | 6.82M | Short Float | 0.28% | Short Ratio | 1.63 |
| Short Interest | — | 52W High | 7.05 | 52W Low | 1.73 |
| Beta | 0.09 | Avg Volume | 30.37K | Volume | 843.00 |
| Target Price | — | Recom | None | Prev Close | $2.32 |
| Price | $2.28 | Change | -1.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.14
Latest analyst target
3. DCF / Fair value
$-24.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.14
Low
—
High
—
Mean
—
- XORTX Therapeutics Inc. (XRTX) stock price, news, quote and history - Yahoo Finance UK hu, 02 Apr 2026 19
- Every 5 XORTX shares become 1 on April 6 after approvals - Stock Titan Wed, 01 Apr 2026 17
- XORTX Therapeutics Inc. (XRTX) stock price, news, quote and history - Yahoo Finance Singapore Wed, 01 Apr 2026 18
- XORTX Shareholders Approve Reverse Split to Preserve Nasdaq Listing - The Globe and Mail Wed, 25 Mar 2026 21
- XORTX Therapeutics Inc.: Dividend historical data and projections - marketscreener.com Fri, 03 Apr 2026 09
- XORTX (XRTX) wins approvals for 1-for-5 share consolidation effective April 6, 2026 - Stock Titan Wed, 01 Apr 2026 17
- XORTX Shareholders Approve Governance Measures and Share Consolidation at Annual Meeting - The Globe and Mail Fri, 27 Mar 2026 07
- XORTX shrinks shares from 6.96M to 1.39M to stay on Nasdaq - Stock Titan Wed, 25 Mar 2026 07
- XORTX's 5-for-1 share consolidation is now scheduled for April 6 - Stock Titan hu, 26 Mar 2026 07
- Only 35% of XORTX shares voted, but every meeting item passed - Stock Titan hu, 26 Mar 2026 07
- If You Invested $1,000 in Xortx Therapeutics Inc (XRTX) - Stock Titan Mon, 23 Mar 2026 03
- XORTX needs its stock above $1. Shareholders approved a 5-for-1 consolidation - Stock Titan ue, 24 Mar 2026 07
- Kidney drug deal: XORTX gets more time to close Vectus buy - Stock Titan Wed, 04 Feb 2026 08
- XORTX Therapeutics (NASDAQ: XRTX) shareholders approve board, stock plan and share consolidation - Stock Titan Fri, 27 Mar 2026 10
- XORTX (NASDAQ: XRTX) moves 1-for-5 share consolidation to April 6 - Stock Titan hu, 26 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
3.26
-20.94%
|
4.12
-31.88%
|
6.05
-41.25%
|
10.29
|
| Research And Development |
|
0.57
+212.75%
|
0.18
-92.40%
|
2.42
-64.23%
|
6.76
|
| Selling General And Administration |
|
1.83
-19.79%
|
2.28
+2.51%
|
2.23
-7.13%
|
2.40
|
| General And Administrative Expense |
|
1.83
-19.79%
|
2.28
+2.51%
|
2.23
-7.13%
|
2.40
|
| Salaries And Wages |
|
0.24
-17.18%
|
0.29
-3.24%
|
0.30
-50.80%
|
0.61
|
| Other Gand A |
|
1.59
-20.18%
|
1.99
+3.41%
|
1.93
+7.77%
|
1.79
|
| Other Operating Expenses |
|
0.74
-51.92%
|
1.53
+21.72%
|
1.26
+17.55%
|
1.07
|
| Total Expenses |
|
3.26
-20.94%
|
4.12
-31.88%
|
6.05
-41.25%
|
10.29
|
| Operating Income |
|
-3.26
+20.94%
|
-4.12
+31.88%
|
-6.05
+41.25%
|
-10.29
|
| EBITDA |
|
-3.14
+21.42%
|
-4.00
+32.26%
|
-5.91
+42.28%
|
-10.23
|
| Normalized EBITDA |
|
-3.70
+20.97%
|
-4.68
+50.90%
|
-9.54
+24.88%
|
-12.70
|
| Reconciled Depreciation |
|
0.11
-4.40%
|
0.12
-16.05%
|
0.14
+140.25%
|
0.06
|
| EBIT |
|
-3.26
+20.94%
|
-4.12
+31.88%
|
-6.05
+41.25%
|
-10.29
|
| Total Unusual Items |
|
0.56
-18.33%
|
0.68
-81.21%
|
3.63
+47.25%
|
2.47
|
| Total Unusual Items Excluding Goodwill |
|
0.56
-18.33%
|
0.68
-81.21%
|
3.63
+47.25%
|
2.47
|
| Special Income Charges |
|
-0.00
|
0.00
|
0.00
+100.00%
|
-0.93
|
| Impairment Of Capital Assets |
|
0.00
|
0.00
|
0.00
|
—
|
| Restructuring And Mergern Acquisition |
|
—
|
0.28
|
0.00
-100.00%
|
0.93
|
| Net Income |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Pretax Income |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Net Non Operating Interest Income Expense |
|
0.04
-65.65%
|
0.12
-51.92%
|
0.25
+144.76%
|
0.10
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
0.04
-65.65%
|
0.12
-51.92%
|
0.25
+144.76%
|
0.10
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
0.04
-65.65%
|
0.12
-51.92%
|
0.25
+150.12%
|
0.10
|
| Interest Income |
|
0.04
-65.65%
|
0.12
-51.92%
|
0.25
+150.12%
|
0.10
|
| Other Income Expense |
|
0.56
-18.33%
|
0.68
-81.21%
|
3.63
+47.25%
|
2.47
|
| Gain On Sale Of Security |
|
0.56
-18.06%
|
0.68
-81.21%
|
3.63
+7.06%
|
3.39
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Net Income From Continuing Operation Net Minority Interest |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Net Income From Continuing And Discontinued Operation |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Net Income Continuous Operations |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Normalized Income |
|
-3.21
+19.57%
|
-4.00
+31.01%
|
-5.79
+43.14%
|
-10.19
|
| Net Income Common Stockholders |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Diluted EPS |
|
—
|
-5.75
-5.50%
|
-5.45
+76.85%
|
-23.54
|
| Basic EPS |
|
—
|
-5.75
-5.50%
|
-5.45
+76.85%
|
-23.54
|
| Basic Average Shares |
|
—
|
0.58
+45.25%
|
0.40
+33.91%
|
0.30
|
| Diluted Average Shares |
|
—
|
0.58
+45.25%
|
0.40
+33.91%
|
0.30
|
| Diluted NI Availto Com Stockholders |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Amortization |
|
0.03
-15.08%
|
0.03
-53.37%
|
0.07
+290.19%
|
0.02
|
| Amortization Of Intangibles Income Statement |
|
0.03
-15.08%
|
0.03
-53.37%
|
0.07
+290.19%
|
0.02
|
| Depreciation Amortization Depletion Income Statement |
|
0.11
-4.40%
|
0.12
-16.05%
|
0.14
+140.25%
|
0.06
|
| Depreciation And Amortization In Income Statement |
|
0.11
-4.40%
|
0.12
-16.05%
|
0.14
+140.25%
|
0.06
|
| Depreciation Income Statement |
|
0.09
-0.55%
|
0.09
+17.99%
|
0.07
+77.90%
|
0.04
|
| Total Other Finance Cost |
|
-0.04
+65.65%
|
-0.12
+51.92%
|
-0.25
-144.76%
|
-0.10
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
2.68
-34.46%
|
4.09
-25.12%
|
5.47
-55.81%
|
12.37
|
| Current Assets |
|
1.26
-52.89%
|
2.68
-34.21%
|
4.07
-62.66%
|
10.90
|
| Cash Cash Equivalents And Short Term Investments |
|
0.86
-65.05%
|
2.47
-28.25%
|
3.45
-66.96%
|
10.43
|
| Cash And Cash Equivalents |
|
0.86
-65.05%
|
2.47
-28.25%
|
3.45
-66.96%
|
10.43
|
| Cash Equivalents |
|
0.62
-74.36%
|
2.42
-27.82%
|
3.35
-49.29%
|
6.61
|
| Cash Financial |
|
0.24
+354.54%
|
0.05
-43.49%
|
0.09
-97.52%
|
3.82
|
| Receivables |
|
0.08
+354.57%
|
0.02
-70.95%
|
0.06
-25.74%
|
0.08
|
| Accounts Receivable |
|
0.08
+354.57%
|
0.02
-70.95%
|
0.06
-25.74%
|
0.08
|
| Prepaid Assets |
|
0.02
-87.81%
|
0.19
-21.76%
|
0.24
-37.58%
|
0.38
|
| Current Deferred Assets |
|
0.29
|
0.00
-100.00%
|
0.32
|
0.00
|
| Total Non Current Assets |
|
1.42
+0.32%
|
1.42
+1.33%
|
1.40
-5.36%
|
1.48
|
| Net PPE |
|
0.04
+6.75%
|
0.03
+45.11%
|
0.02
-74.18%
|
0.09
|
| Gross PPE |
|
0.32
+37.49%
|
0.23
+70.32%
|
0.14
+3.23%
|
0.13
|
| Accumulated Depreciation |
|
-0.29
-42.82%
|
-0.20
-75.61%
|
-0.11
-178.45%
|
-0.04
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.30
+41.63%
|
0.21
+84.65%
|
0.11
+0.00%
|
0.11
|
| Other Properties |
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
+22.65%
|
0.02
|
| Goodwill And Other Intangible Assets |
|
0.19
+1.23%
|
0.18
+4.48%
|
0.18
-12.30%
|
0.20
|
| Other Intangible Assets |
|
0.19
+1.23%
|
0.18
+4.48%
|
0.18
-12.30%
|
0.20
|
| Non Current Accounts Receivable |
|
1.20
+0.00%
|
1.20
+0.00%
|
1.20
+1.19%
|
1.19
|
| Total Liabilities Net Minority Interest |
|
0.60
-20.97%
|
0.76
-8.23%
|
0.83
-84.64%
|
5.38
|
| Current Liabilities |
|
0.60
-20.97%
|
0.76
-8.23%
|
0.83
-45.35%
|
1.51
|
| Payables And Accrued Expenses |
|
0.55
+276.20%
|
0.15
-48.06%
|
0.28
-80.39%
|
1.45
|
| Payables |
|
0.40
+370.77%
|
0.08
-57.09%
|
0.20
-84.87%
|
1.29
|
| Accounts Payable |
|
0.40
+370.77%
|
0.08
-57.09%
|
0.20
-84.87%
|
1.29
|
| Current Accrued Expenses |
|
0.16
+150.45%
|
0.06
-27.88%
|
0.09
-42.13%
|
0.15
|
| Current Debt And Capital Lease Obligation |
|
0.04
-3.86%
|
0.04
+236.97%
|
0.01
-82.58%
|
0.07
|
| Current Capital Lease Obligation |
|
0.04
-3.86%
|
0.04
+236.97%
|
0.01
-82.58%
|
0.07
|
| Other Current Liabilities |
|
0.01
-98.60%
|
0.57
+7.72%
|
0.53
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
3.87
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Stockholders Equity |
|
2.08
-37.53%
|
3.34
-28.12%
|
4.64
-33.66%
|
7.00
|
| Common Stock Equity |
|
2.08
-37.53%
|
3.34
-28.12%
|
4.64
-33.66%
|
7.00
|
| Capital Stock |
|
20.18
+9.14%
|
18.49
+8.43%
|
17.06
+3.22%
|
16.52
|
| Common Stock |
|
20.18
+9.14%
|
18.49
+8.43%
|
17.06
+3.22%
|
16.52
|
| Share Issued |
|
6.96
+99.98%
|
3.48
+74.17%
|
2.00
+19.69%
|
1.67
|
| Ordinary Shares Number |
|
6.96
+99.98%
|
3.48
+74.17%
|
2.00
+19.69%
|
1.67
|
| Retained Earnings |
|
-23.82
-12.55%
|
-21.17
-18.56%
|
-17.85
-13.75%
|
-15.70
|
| Gains Losses Not Affecting Retained Earnings |
|
5.73
-4.36%
|
5.99
+11480.05%
|
-0.05
+0.00%
|
-0.05
|
| Other Equity Adjustments |
|
5.73
-4.36%
|
5.99
+11480.05%
|
-0.05
+0.00%
|
-0.05
|
| Total Equity Gross Minority Interest |
|
2.08
-37.53%
|
3.34
-28.12%
|
4.64
-33.66%
|
7.00
|
| Total Capitalization |
|
2.08
-37.53%
|
3.34
-28.12%
|
4.64
-33.66%
|
7.00
|
| Working Capital |
|
0.66
-65.50%
|
1.92
-40.83%
|
3.24
-65.44%
|
9.38
|
| Invested Capital |
|
2.08
-37.53%
|
3.34
-28.12%
|
4.64
-33.66%
|
7.00
|
| Total Debt |
|
0.04
-3.86%
|
0.04
+236.97%
|
0.01
-85.17%
|
0.08
|
| Capital Lease Obligations |
|
0.04
-3.86%
|
0.04
+236.97%
|
0.01
-85.17%
|
0.08
|
| Net Tangible Assets |
|
1.90
-39.78%
|
3.15
-29.40%
|
4.47
-34.28%
|
6.80
|
| Tangible Book Value |
|
1.90
-39.78%
|
3.15
-29.40%
|
4.47
-34.28%
|
6.80
|
| Derivative Product Liabilities |
|
—
|
—
|
0.53
-86.22%
|
3.85
|
| Other Equity Interest |
|
—
|
0.02
-99.55%
|
5.49
-11.72%
|
6.22
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-2.77
+24.74%
|
-3.68
+44.12%
|
-6.58
+19.38%
|
-8.17
|
| Cash Flow From Continuing Operating Activities |
|
-2.77
+24.74%
|
-3.68
+44.12%
|
-6.58
+19.38%
|
-8.17
|
| Net Income From Continuing Operations |
|
-2.66
+19.83%
|
-3.31
-53.53%
|
-2.16
+72.04%
|
-7.72
|
| Depreciation Amortization Depletion |
|
0.11
-4.40%
|
0.12
-16.05%
|
0.14
+140.25%
|
0.06
|
| Depreciation |
|
0.09
-0.55%
|
0.09
+17.99%
|
0.07
+77.90%
|
0.04
|
| Amortization Cash Flow |
|
0.03
-15.08%
|
0.03
-53.37%
|
0.07
+290.19%
|
0.02
|
| Depreciation And Amortization |
|
0.11
-4.40%
|
0.12
-16.05%
|
0.14
+140.25%
|
0.06
|
| Amortization Of Intangibles |
|
0.03
-15.08%
|
0.03
-53.37%
|
0.07
+290.19%
|
0.02
|
| Other Non Cash Items |
|
—
|
—
|
—
|
0.00
|
| Stock Based Compensation |
|
0.03
-79.47%
|
0.12
+1.28%
|
0.12
-75.21%
|
0.49
|
| Provisionand Write Offof Assets |
|
—
|
—
|
—
|
0.00
|
| Asset Impairment Charge |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Gains Losses |
|
-0.59
+18.58%
|
-0.72
+80.25%
|
-3.66
-48.16%
|
-2.47
|
| Gain Loss On Investment Securities |
|
-0.56
+25.40%
|
-0.76
+79.24%
|
-3.64
-47.99%
|
-2.46
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.02
-169.46%
|
0.03
+350.68%
|
-0.01
-113.33%
|
-0.01
|
| Change In Working Capital |
|
0.34
+187.87%
|
0.12
+111.33%
|
-1.03
-169.94%
|
1.47
|
| Change In Receivables |
|
-0.06
-245.18%
|
0.04
+104.71%
|
0.02
+151.20%
|
-0.04
|
| Changes In Account Receivables |
|
-0.06
-245.18%
|
0.04
+104.71%
|
0.02
+151.20%
|
-0.04
|
| Change In Prepaid Assets |
|
0.16
-21.79%
|
0.21
+45.92%
|
0.14
-77.09%
|
0.62
|
| Change In Payables And Accrued Expense |
|
0.24
+275.50%
|
-0.13
+88.74%
|
-1.19
-233.87%
|
0.89
|
| Investing Cash Flow |
|
-0.29
-657.77%
|
-0.04
+16.05%
|
-0.05
-1.45%
|
-0.05
|
| Cash Flow From Continuing Investing Activities |
|
-0.29
-657.77%
|
-0.04
+16.05%
|
-0.05
-1.45%
|
-0.05
|
| Net PPE Purchase And Sale |
|
0.00
|
0.00
+100.00%
|
-0.00
+78.11%
|
-0.02
|
| Purchase Of PPE |
|
0.00
|
0.00
+100.00%
|
-0.00
+78.11%
|
-0.02
|
| Capital Expenditure |
|
-0.06
-41.87%
|
-0.04
+16.05%
|
-0.05
-1.45%
|
-0.05
|
| Net Intangibles Purchase And Sale |
|
-0.06
-41.87%
|
-0.04
+7.44%
|
-0.04
-61.71%
|
-0.03
|
| Purchase Of Intangibles |
|
-0.06
-41.87%
|
-0.04
+7.44%
|
-0.04
-61.71%
|
-0.03
|
| Net Other Investing Changes |
|
-0.24
|
—
|
—
|
—
|
| Financing Cash Flow |
|
1.43
-48.64%
|
2.78
+869.85%
|
-0.36
-109.23%
|
3.91
|
| Cash Flow From Continuing Financing Activities |
|
1.43
-48.64%
|
2.78
+869.85%
|
-0.36
-109.23%
|
3.91
|
| Net Issuance Payments Of Debt |
|
-0.09
-28.47%
|
-0.07
-5.50%
|
-0.07
-223.81%
|
-0.02
|
| Repayment Of Debt |
|
-0.09
-28.47%
|
-0.07
-5.50%
|
-0.07
-223.81%
|
-0.02
|
| Long Term Debt Payments |
|
-0.09
-28.47%
|
-0.07
-5.50%
|
-0.07
-223.81%
|
-0.02
|
| Net Long Term Debt Issuance |
|
-0.09
-28.47%
|
-0.07
-5.50%
|
-0.07
-223.81%
|
-0.02
|
| Net Common Stock Issuance |
|
2.26
-35.57%
|
3.50
|
0.00
-100.00%
|
5.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-99.92%
|
0.02
+5498.99%
|
0.00
+362.50%
|
0.00
|
| Net Other Financing Charges |
|
-0.74
-10.56%
|
-0.67
-126.21%
|
-0.30
+72.33%
|
-1.07
|
| Changes In Cash |
|
-1.64
-74.42%
|
-0.94
+86.58%
|
-6.99
-62.59%
|
-4.30
|
| Effect Of Exchange Rate Changes |
|
0.03
+175.09%
|
-0.04
-989.71%
|
0.00
+102.97%
|
-0.14
|
| Beginning Cash Position |
|
2.47
-28.25%
|
3.45
-66.96%
|
10.43
-29.83%
|
14.87
|
| End Cash Position |
|
0.86
-65.05%
|
2.47
-28.25%
|
3.45
-66.96%
|
10.43
|
| Free Cash Flow |
|
-2.82
+24.04%
|
-3.72
+43.92%
|
-6.63
+19.27%
|
-8.21
|
| Common Stock Issuance |
|
2.26
-35.57%
|
3.50
|
0.00
-100.00%
|
5.00
|
| Issuance Of Capital Stock |
|
2.26
-35.57%
|
3.50
|
0.00
-100.00%
|
5.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|